

Volume 45 • Supplement 1 • September 2017

INFECTION

Official Publication of the German Society for Infectious Diseases
and the Italian Society of Infectious and Tropical Diseases

Abstracts

Weimar Sepsis Update 2017 – Facing the Challenges
September 6–8, 2017, Weimar, Germany

SUPPLEMENT

 Springer

Infection

A Journal of Infectious Disease

Official Publication of the German Society for Infectious Diseases (DGI) and the Italian Society of Infectious and Tropical Diseases (SIMIT)

Cooperation with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), German Sepsis Society (DSG) and the Paul Ehrlich Society for Chemotherapy (PEG)

Editor-in-Chief

J. R. Bogner, Munich, Germany
Sektion Klinische Infektiologie
Klinik und Poliklinik IV
Klinikum der Universität München
Pettenkoferstr. 8a
80336 München, Germany
Tel.: +49-(0)89-4400-53598
e-mail: Johannes.Bogner@med.uni-muenchen.de

Editors

E. Sagnelli, Caserta, Italy (SIMIT)
N. Suttorp, Berlin, Germany (DGI)

Clinical infectious diseases

B. Salzberger, Regensburg, Germany
G. Weiss, Innsbruck, Austria

Pediatric infectious diseases

D. Nadal, Zurich, Switzerland

Clinical microbiology

S. Esposito, Salerno, Italy
H. Seifert, Cologne, Germany

Healthcare-associated infections, Antimicrobial use, Healthcare quality

J. Kluytmans, Breda, The Netherlands
C. Ruef, Zurich, Switzerland

Fungal infections

C. Lass-Flörl, Innsbruck, Austria
A. Ullmann, Würzburg, Germany

Viral infections

G. Fätkenheuer, Cologne, Germany

Parasitic infections & international health

G. Calleri, Torino, Italy
M. Grobusch, Amsterdam, The Netherlands

W. Marget (Founding Editor)[†]

Editorial Board

A. Antinori, Rome, Italy
R.D. Arbeit, Boston, MA, USA
M. Battegay, Basel, Switzerland
S. Bélard, Berlin, Germany
J.M. Boyce, New Haven, CT, USA
G. Carosi, Brescia, Italy (SIMIT)
F. Castelli, Brescia, Italy
R. Cauda, Rome, Italy
F. Chang, Taipei, Taiwan
G.A. da Silva, Rio de Janeiro, Brazil
A. Dalhoff, Wuppertal, Germany
A. D'Arminio Monforte, Milan, Italy
P. Deplazes, Zurich, Switzerland
M. Dettenkofer, Freiburg, Germany
H.W. Doerr, Frankfurt a. M., Germany
F.D. Goebel, Munich, Germany
B. Goorhuis, Amsterdam, The Netherlands
L. Gürtler, Greifswald, Germany
M. Hui, Hong Kong, China
S. Janssen, Amsterdam, The Netherlands
W. Kern, Freiburg, Germany
B. Knoll, Providence, USA
C. Lange, Borstel, Germany
C. Lehmann, Cologne, Germany
H. Lode, Berlin, Germany
T. Löscher, Munich, Germany
F. Mazzotta, Antella, Italy
J.W. Mouton, SZ Nijmegen, The Netherlands
E. Nulens, Brugge, Belgium
G. Peters, Münster, Germany
H.W. Pfister, Munich, Germany
M. Pletz, Jena, Germany
K. Rolston, Houston, TX, USA
M. Sagar, Boston, USA
M. Salfinger, Denver, USA
W. Schaffner, Nashville, TN, USA
U. Seybold, Munich, Germany
F. Strle, Ljubljana, Slovenia
M. Struelens, Bruxelles, Belgium
J. Treanor, Rochester, NY, USA
A. von Graevenitz, Zurich, Switzerland
M. Weiss, Cologne, Germany
C. Wejse, Aarhus, Denmark
L. Zammarchi, Florence, Italy
W. Zimmerli, Liestal, Switzerland

Abstracts

8th International Congress “Sepsis and Multiorgan Dysfunction”

Weimar Sepsis Update 2017– Facing the Challenges

September 6–8, 2017

Weimar

Organizer

H. Gerlach

T. Welte

F. M. Brunkhorst

Guest Editors

F. M. Brunkhorst

T. Welte

H. Gerlach

German Sepsis Society (DSG)
<http://www.sepsis-gesellschaft.de>

Contents

Abstract

Experimental Sepsis Research S4

Abstracts 006, 007, 012, 023, 024, 029, 030, 032, 033, 037, 038, 039, 040, 041, 042, 043, 044, 046, 047, 052, 056, 059, 060, 061, 063, 066, 067, 073, 079, 080, 081, 082, 083, 084, 085, 086, 090, 091, 099, 101, 102, 104, 105, 106, 111, 113, 114, 115

Clinical Sepsis Research – Diagnostics S27

Abstracts 001, 003, 004, 008, 009, 010, 011, 013, 022, 025, 034, 035, 048, 054, 055, 058, 069, 070, 071, 072, 077, 087, 088, 089, 093, 098, 103, 108, 110, 112, 118

Clinical Sepsis Research – Therapy S43

Abstracts 014, 015, 019, 020, 021, 028, 031, 036, 049, 050, 053, 064, 065, 068, 074, 075, 076, 092, 096, 100, 107, 109, 119, 120

Longterm Outcome S56

Abstracts 002, 026, 027, 045, 057, 094, 095, 097, 116, 117

Sepsis Prevention S61

Abstracts 017, 018, 062, 078

This supplement was not sponsored by outside commercial interests. It was funded entirely by the German Sepsis Society.

Drug-resistant pathogen challenges of Seraph 200 by Battelle used a swine model. Bacteria were infused continuously at concentrations between 400 and 3100 CFU/mL into a prototype extracorporeal hemoperfusion circuit. Blood samples were collected contemporaneously before and after Seraph to quantify bacteria removal by the device.

Results: In vitro results demonstrated efficient single-pass removal of drug-resistant bacteria strains: MRSA (92%), MRSE (66%), CRE *E. coli* (99.9%), CRE *K. pneumoniae* (99.9%), VRE *E. faecalis* (91%), and ESBL *K. pneumoniae* (39%). The Battelle porcine model demonstrated that Seraph 200 could continuously remove MRSA (78–88%), MDR (79%), MDR *P. aeruginosa* (83%), and MDR *K. pneumoniae* (35%).

Conclusions: In vivo pre-clinical feasibility studies have been confirmed in an ongoing German clinical trial using Seraph in a 4-h therapy during hemodialysis. Human and pre-clinical animal testing support the use of Seraph therapy as an adjunctive tool to improve the therapeutic efficiency of currently available drugs, or when no effective antimicrobial drugs are available.

References: 1. Opal, Steven M. 2016, Critical Care, Vol. 20, 397.
2. E. Tacconelli, et al. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. s.l. : World Health Organization, 2017.
3. Seymour, C W, et al. 23, 2017, The New England Journal of Medicine, Vol. 376, 2235-2244.
4. Kirkbright. 2011, Emergence Medicine Australasia, Vol. 23, 502.

066

Infection 2017

Survival and function in rats with genetic predisposition for high or low exercise capacity

Schwarzer M (1), Marx J (1), Schenk C (1), Koch LG (2), Britton SL (3), Doenst T (1)

(1) Department of cardiothoracic Surgery, University Hospital Jena, (2) Department of Anesthesiology, The University of Michigan, (3) Department of Molecular and Integrative Physiology, Department of Anesthesiology, The University of Michigan.

Introduction: Sepsis may lead to multiple organ failure and death. Sepsis-induced cardiac dysfunction represents one of several possible complications and is co-responsible for the high mortality typical for sepsis. It is accepted that physical fitness as well as high intrinsic exercise capacity positively influences cardiovascular health. However, less is known about the impact of these factors on cardiac performance and metabolism in sepsis.

Objectives: We aimed to identify the effect of sepsis on cardiac function, metabolism and insulin responsiveness in rats differing in their genetic predisposition for either high or low inborn exercise capacity.

Methods: Sepsis was induced in 15-week old rats with high (HCR) or low (LCR) intrinsic running capacity by intraperitoneal injection of a human fecal suspension. The Clinical Severity Score (CSS) was determined to assess sepsis severity 6 and 24 h later. At 1 and 5 weeks, hearts from sepsis survivors were excised and prepared as isolated working hearts. Cardiac function, substrate oxidation and response to insulin were measured using radioactive tracer technology.

Results: The two groups did not differ in their CSS scores at 6 and 24 h and survival was poor with 33% (HCR) and 38% (LCR) survivors at 72 h. After 5 weeks, septic animals displayed substantial reductions of cardiac power (Control vs 5w of sepsis: 45.6 ± 2.9 vs. 37.6 ± 1.5 , $p < 0.05$ mW/g dry). This reduction in power was not

associated with sepsis-induced alterations in glucose oxidation (0.33 ± 0.06 vs. 0.30 ± 0.05 $\mu\text{mol}/\text{min}/\text{g}$ dry, n.s.) or fatty acid oxidation (0.67 ± 0.08 vs. 0.70 ± 0.05 $\mu\text{mol}/\text{min}/\text{g}$ dry, n.s.). However, when relating substrate oxidation to cardiac power as a measure of substrate efficacy, there was an increase in substrate used per force. Insulin response was increased in HCR only (change of glucose oxidation: $+0.32 \pm 0.08$ vs. $+0.39 \pm 0.07$ and $+0.16 \pm 0.04$ vs. $+0.51 \pm 0.11$ $\mu\text{mol}/\text{min}/\text{g}$ dry, $p < 0.05$).

Conclusions: The detrimental effects of sepsis on survival in rats are not affected by their genetically determined exercise capacity. Sepsis causes significant mortality and contractile dysfunction in survivors. This dysfunction was accompanied by maintained glucose and fatty acid oxidation suggesting significantly decreased efficiency of substrate use.

067

Infection 2017

Microbiota of the albino rats ileum lumen under abdominal sepsis

Sydorchuk LI (1), Sydorchuk AS (2), Sydorchuk I (1), Sydorchuk RI (3)

(1) Microbiology Department, Bukovinian State Medical University, (2) Infectious Diseases Department, Bukovinian State Medical University, (3) General Surgery Department, Bukovinian State Medical University.

Introduction: Microflora of the distal part of ileum plays a separate role in formation of abdominal sepsis (AS) and is characterized by enhanced vascularization and localization of mucous-associated lymphoid clusters, which provides a significant ability to resorption of antigens in comparison with other parts of the gastrointestinal tract.

Objectives: To study the qualitative and quantitative composition of the microbiota of the ileum lumen of albino rats with AS.

Methods: A bacteriological method was used in 25 white rats (200–220 g). All animals were quarantined for 10–14 days. Ten rats with induced AS concluded the main group, 15 intact animals formed the control. Before the study all animals were examined for possible pathology. In sterile conditions, the abdominal cavity was opened, a portion (1.5–2 cm) of the distal part of ileum with its contents was taken. Pure cultures were identified by morphological, tinctorial, cultural and biochemical properties.

Results: In animals with experimental AS the dominant microflora of ileum lumen consists of obligate anaerobic bacteria of the genera Bacteroides, Bifidobacterium, Lactobacillus, Peptostreptococcus, facultative anaerobic and aerobic opportunistic enterobacteria: *E. coli* and Proteus; additional microflora is formed by the bacteria of the genus Enterococcus and accidental—by Peptococcus and Klebsiella. Also, it should be noticed the elimination of the genera Bifidobacterium and Lactobacillus from the iliac lumen in 20.0% of the animals and the contamination and colonization of the biotope with the conditionally pathogenic enterobacteria of the genera Klebsiella and Proteus. The results of the bacteriological study confirm the moderate deficiency of the most important for composition of the intestinal microbiocenosis and multifunctional role in maintaining the microecological homeostasis bacteria of the genus Bifidobacterium (reduction by 33.91%) and Lactobacillus (reduction by 27.53%), as well as a less significant decrease in the population level of bacteria of genera Bacteroides (19.85%), Peptostreptococcus (13.88%), Escherichia (8.97%), Enterococcus (8.97%) etc. The number of Proteus in the microbiocenosis is increased by 10.33%; Klebsiella reached a moderate population level. Changes of the population level of bacteria of different taxons lead to an imbalance of microbiocenosis of

oxidation fatty acid (s.). How-a measure per force. f glucose 0.04 vs.

n rats are ty. Sepsis survivors. and fatty y of sub-

al sepsis rchuk RI

iversity, Medical ite Med-

separate ized by sociated sorption itestinal

ition of

ite rats en rats formed possible ened, a its was ctorial,

flora of genera occus, *E. coli* of the siella. dobac-nimals e con-a and derate astinal icroe-erium %), as ria of scher-us in hed a bac-sis of

the ileum lumen, which is more clearly indicated by other analytical indices. Thus, in *Bifidobacterium* the quantitative dominance is reduced by 44.88%, participation in the formation of microbiocenosis of the biotope by 50.98%; in *Lactobacilli* by 37.02 and 36.01% respectively, in *Enterococci*—by 3.5 times and 4.51 times respectively. The quantitative dominance and participation in the formation of the microbiocenosis of opportunistic enterobacteria increased by 32.37 and 57.96%.

Conclusions: AS leads to deficiency and in some cases (20.0%) to elimination of *Bifidobacterium*, *Lactobacillus* and contamination and colonization of the ileum lumen with opportunistic enterobacteria (*Klebsiella*, *Proteus*).

073

Infection 2017

Role of AMPK in systemic inflammation

Lindenmüller S (1), von Loeffelholz C (2), Thuy A (2), Castanares-Zapatero D (3), Gräler M (2), Horman S (3), Viollet B (4), Heller R (1)

(1) *Integrated Research and Treatment Center, Center for Sepsis Control and Care and Institute of Molecular Cell Biology, Jena University Hospital, Friedrich Schiller University, Jena, Germany*, (2) *Integrated Research and Treatment Center, Center for Sepsis Control and Care and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich Schiller University, Jena, Germany*, (3) *Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium*, (4) *Institut Cochin, Université Paris Descartes, CNRS, France*.

Introduction: The systemic inflammatory response syndrome (SIRS) is characterised by endothelial and microvascular dysfunction resulting in decreased organ perfusion and subsequent development of organ failure. The energy-sensing enzyme AMP-activated kinase (AMPK), a crucial regulator of cell metabolism and homeostasis, is thought to play an important role in inflammatory processes. It exerts significant anti-inflammatory and antioxidant effects in a variety of cell types, in part by inhibiting the pro-inflammatory NF- κ B pathway. **Objectives:** We hypothesised that AMPK may control SIRS and limit inflammatory responses of the endothelium thereby protecting against vascular dysfunction.

Methods: Experiments were performed in wild type (WT) mice and in mice, in which the catalytic subunit AMPK α 1 was knocked out (KO). SIRS was induced by intraperitoneal injection of LPS (10 μ g/g body weight). To investigate differences in WT and KO mice, plasma cytokine levels and markers of cellular damage as well as cytokine levels in the liver were analysed. To characterise the influence of AMPK on endothelial permeability in vivo, a vascular leakage assay employing Evans Blue was performed. In vitro experiments were performed in human umbilical vein endothelial cells, which were stimulated with cytokines (IL-1 β , TNF- α) and/or LPS and analysed for permeability (ECIS) and adhesion molecule expression (flow cytometry). AICAR and A769662 were used to activate AMPK in these experiments.

Results: Female WT mice showed a higher survival compared to male WT mice in response to LPS. Knockout of AMPK α 1 reduced survival in female mice but had no effect on mortality in male mice. In line with this, higher plasma cytokine levels (IL1 β , TNF α) and increased plasma markers of cellular damage (lactate dehydrogenase) were observed in female AMPK α 1 KO mice indicating protection from systemic inflammation by AMPK α 1.

6 h after LPS injection, a significant vascular leakage as monitored with Evans Blue was seen in organs including liver. Here, no gender difference was observed. LPS-induced vascular leakage in liver was clearly higher in AMPK α 1 KO mice compared to WT mice. In parallel, cytokine levels (IL-1 β , TNF- α) in liver and plasma markers of hepatocellular damage (alanine aminotransferase, aspartate aminotransferase) were increased in AMPK α 1 KO animals. These data indicate that AMPK α 1 protects from vascular leakage and liver inflammation during SIRS. This may be in part due to endothelial barrier stabilisation and prevention of leukocyte immigration into the tissue. Accordingly, pharmacological activation of AMPK in cultured endothelial cells led to a significant decrease of cytokine-induced endothelial permeability and adhesion molecule expression.

Conclusions: Taken together, these data underline the importance of AMPK as an anti-inflammatory molecule in the context of systemic and local inflammation. AMPK may represent a pharmacological target to prevent or ameliorate inflammatory responses during SIRS.

079

Infection 2017

TLR-expressing cells as biosensor for bacterial ligands

Reuter S (1), Westphal A (1), Herold K (1), Sponholz C (2), Bauer M (2), Mrowka R (1)

(1) *Experimental Nephrology, University Hospital Jena*, (2) *Department of Anesthesiology and Intensive Care Medicine, University Hospital Jena*.

Introduction: The early recognition of potentially pathogenic microorganisms is the essential step before mechanisms of innate and adaptive immune responses are initiated. The evolutionary battle between host and pathogens lead to the development of the Toll-like receptor system for the recognition of bacterial, fungal and viral components of very different chemical composition. Bacterial and fungal cell wall components, proteins, toxins and nucleic acids belong to those molecules and the binding of the so-called pathogen-associated molecular patterns (PAMPs) to Toll-like receptors (TLRs) provokes a signaling cascade resulting in recruitment of the transcription factor NF- κ B. NF- κ B binds to certain NF- κ B response elements in the promotor region of genes involved in inflammation and immunity and activates their transcription. The recognition process takes place soon after microorganisms overcome the barriers of skin and mucosa by tissue resident immune cells carrying TLRs and also other immune receptors.

Objectives: We generated a TLR expression based cellular assay to detect bacterial ligands in liquid samples. Our intention is to use reporter cell lines to measure the activation and signalling of certain Toll-like receptors to evaluate blood plasma samples from septic patients.

Methods: We generated stable isogenic cell lines expressing single TLRs (e.g. TLR5) or combinations of TLRs and cofactors (e.g. TLR4). The cells are seeded in 96 well plates and stimulated after 14–16 h of adherence. The cells were stimulated with soluble ligands, heat-inactivated bacteria and more complex samples e.g. spiked plasma samples and blood plasma from septic patients.

Results: Cells expressing TLR2, TLR2/TLR1, TLR2/TLR6, TLR4-CD14-MD2 or TLR5 were dose-dependently activated by the according ligands lipoteichoic acid, Pam3Csk4, Fsl-1, LPS and Flagellin as well as by heat-inactivated bacteria and spiked human plasma samples. Septic plasma samples activated several TLR-expressing cell lines according to the causing microorganism.